57-85-2

• 常用中文名：丙酸睾丸酮
• 常用英文名：Testosterone propionate
• CAS号：57-85-2
• 分子式：C₂₂H₃₂O₃
• 分子量：344.488
• 相关类别： 原料药 激素及调节内分泌功能类药 雄激素及同化激素类药
• 发布时间：2018-02-03 08:00:00
• 更新时间：2024-01-02 22:56:11
• Testosterone propionate是一种较慢释放的合成代谢类固醇,主要用于治疗男性睾酮水平低。
• 作用与睾酮、甲睾酮相同，但肌注作用时间较持久，每2～3日注射一次即可。临床适用于无睾症、隐睾症、男性性腺机能减退症；妇科疾病如月经过多、子宫肌瘤；老年性骨质疏松以及再生障碍性贫血等。通过刺激肾脏分泌红细胞生成素的作用，或对骨髓有直接刺激作用。原发性睾丸功能减退症的雄激素替代治疗；性器官发育不良。
  大剂量可引起女性男性化、浮肿、肝损害、黄疸、头晕等。有过敏反应者应即停药。肝、肾功能不全、前列腺癌患者及孕妇忌用。注射液如有结晶析出，可加温溶解后注射。青春期发育延迟及侏儒症；各种慢性消耗性疾病等。本品在体先转化为5α二氢睾酮（5α-dihyrotesterone）,以后再与细胞受体结合，进入细胞核，与染色质作用，激活RNA多聚酶，促进蛋白质合成和细胞代谢。此外，丙酸睾酮可通过红细胞生成素刺激红细胞的生成和分化。本品口服虽可吸收，但肝中会迅速破坏而失效，故一般采用肌内注射。肌内注射丙酸睾酮后，吸收较慢，其延效时间2-4天。在血中，98%的睾酮与性激素球蛋白结合，仅2%为游离状。半衰期为10-20分钟。睾酮在肝内灭活后，代谢产物为雄酮异雄酮及原胆烷醇酮。它们90%是与葡萄醛酸及硫酸结合的形式从尿中排出。约6%非结合形式的产物是由胆汁排出，其中少部分仍可再吸收，形成肠肝循环。

名称

• 中文名: 丙酸睾酮
• 英文名: Testosterone Propionate
• 中文别名: 丙睾; 丙酸睾丸酮; 丙酸睾丸酮; 丙酸睾丸素
• 英文别名: TESTOSTERON PROPIONATE; Okasa-Mascul; Testaform; TESTOVIRON; Androst-4-en-3-one, 17- (1-oxopropoxy)-, (17β)-; D4-Androstene-17b-propionate-3-one; 17β-(Propionyloxy)androst-4-en-3-one; Synandrol; VIRORMONE; Solvotest; Masenate; Telipex; MFCD00003653; 17β-Hydroxyandrost-4-en-3-one propionate; Bio-testiculina; Homandren; 17β-Propionyloxy-4-androsten-3-one; Pantestin; Testormol; Testosterone, propionate; Hormoteston; Homandren (VAN); Synerone; Testosid; Androsteston; Testogen; Testoviron (tablet); ORETON; Oreton propionate; Testodrin; 17β-Hydroxy-4-androsten-3-one 17-propionate; EINECS 200-351-1; (17β)-3-Oxoandrost-4-en-17-yl propionate; Propionyltestosterone; Testolets; Androst-4-en-3-one, 17-(1-oxopropoxy)-, (17β)-; Sterandryl; Testoviron (VAN); Agovirin; neo-Hombreol; Aquaviron; Propiokan; Androtest P; Tostrin; Testrex; Enarmon; Uniteston; Andrusol-P; Testoxyl; Orchistin; Orchiol; Nasdol; Androst-4-en-3-one, 17β-hydroxy-, propionate; Enarmon-oil; Andronate; 4-Androsten-17β-ol-3-one 17-propionate; Recthormone testosterone; Vulvan; ANDROLON; Testonique; Testex; Testodet; [(8R,9S,10R,13S,14S,17S)-10,13-dimethyl-3-oxo-1,2,6,7,8,9,11,12,14,15,16,17-dodecahydrocyclopenta[a]phenanthren-17-yl] propanoate; tp; Testosterone propionate; Testosterone (propionate)

物化性质

• 密度: 1.1±0.1 g/cm3
• 沸点: 454.6±45.0 °C at 760 mmHg
• 熔点: 118-123 °C
• 分子式: C₂₂H₃₂O₃
• 分子量: 344.488
• 闪点: 196.3±28.8 °C
• 精确质量: 344.235138
• PSA: 43.37000
• LogP: 4.90
• 外观性状: 白色至灰白色结晶粉末
• 蒸汽压: 0.0±1.1 mmHg at 25°C
• 折射率: 1.538
• 储存条件:

  本品应密封于阴凉干燥处保存。

• 水溶解性: ethanol: 10 mg/mL | <0.1 g/100 mL at 24.5 ºC
• 分子结构:

  五、分子性质数据：

  1、 摩尔折射率：97.32

  2、 摩尔体积（m³/mol）：311.2

  3、 等张比容（90.2K）：792.3

  4、 表面张力（dyne/cm）：42.0

  5、 极化率（10 ^-24cm ³）：38.58

• 计算化学:

  1.疏水参数计算参考值（XlogP）:无

  2.氢键供体数量:0

  3.氢键受体数量:3

  4.可旋转化学键数量:3

  5.互变异构体数量:5

  6.拓扑分子极性表面积43.4

  7.重原子数量:25

  8.表面电荷:0

  9.复杂度:621

  10.同位素原子数量:0

  11.确定原子立构中心数量:6

  12.不确定原子立构中心数量:0

  13.确定化学键立构中心数量:0

  14.不确定化学键立构中心数量:0

  15.共价键单元数量:1

• 更多:

  1. 性状：白色结晶。

  2. 密度（g/mL,25/4℃）： 未确定

  3. 相对蒸汽密度（g/mL,空气=1）：未确定

  4. 熔点（ºC）：118～122

  5. 沸点（ºC,常压）：未确定

  6. 沸点（ºC,5.2kPa）：未确定

  7. 折射率：未确定

  8. 闪点（ºC）：未确定

  9. 比旋光度（º）：[α]D25 +83° +90°（C=0.1，二氧六环中）

  10. 自燃点或引燃温度（ºC）：未确定

  11. 蒸气压（kPa,25ºC）：未确定

  12. 饱和蒸气压（kPa,60ºC）：未确定

  13. 燃烧热（KJ/mol）：未确定

  14. 临界温度（ºC）：未确定

  15. 临界压力（KPa）：未确定

  16. 油水（辛醇/水）分配系数的对数值：未确定

  17. 爆炸上限（%,V/V）：未确定

  18. 爆炸下限（%,V/V）：未确定

  19. 溶解性：易溶于乙醇、乙醚、吡啶和其他有机溶剂，溶于植物油，不溶于水。

生物活性

• 描述: Testosterone propionate是一种较慢释放的合成代谢类固醇,主要用于治疗男性睾酮水平低。
• 相关类别:
  研究领域 >> 其他
  信号通路 >> 其他 >> 雄激素受体

MSDS

1.1 产品标识符 : 丙酸睾酮 产品名称 1.2 鉴别的其他方法 4-Androsten-17β-ol-3-one 17-propionate 17β-Hydroxy-4-androsten-3-one 17-propionate 17β-Propionyloxy-4-androsten-3-one 1.3 有关的确定了的物质或混合物的用途和建议不适合的用途 仅供科研用途，不作为药物、家庭备用药或其它用途。 模块2. 危险性概述 2.1 GHS分类 急性毒性, 经口 (类别4) 致癌性 (类别1B) 致畸性 (类别2) 2.2 GHS 标记要素，包括预防性的陈述 象形图 警示词危险 危险申明 H302吞咽有害。 H350可能致癌。 H361怀疑对生育能力或胎儿造成伤害。 警告申明 预防 P201在使用前获取特别指示。 P202在读懂所有安全防范措施之前切勿操作。 P264操作后彻底清洁皮肤。 P270使用本产品时不要进食、饮水或吸烟。 P281使用所需的个人防护设备。 措施 P301 + P312如果吞下去了: 如感觉不适，呼救解毒中心或看医生。 P308 + P313如接触到或有疑虑：求医/ 就诊。 P330漱口。 储存 P405存放处须加锁。 处理 P501将内容物/ 容器处理到得到批准的废物处理厂。 只限于专业使用者。 2.3 其它危害物 - 无 模块3. 成分/组成信息 3.1 物 质 : 4-Androsten-17β-ol-3-one 17-propionate 别名 17β-Hydroxy-4-androsten-3-one 17-propionate 17β-Propionyloxy-4-androsten-3-one : C22H32O3 分子式 : 344.49 g/mol 分子量 组分浓度或浓度范围 Testosterone propionate - CAS 号57-85-2 EC-编号200-351-1 模块4. 急救措施 4.1 必要的急救措施描述 一般的建议 请教医生。 出示此安全技术说明书给到现场的医生看。 吸入 如果吸入,请将患者移到新鲜空气处。 如果停止了呼吸,给于人工呼吸。 请教医生。 皮肤接触 用肥皂和大量的水冲洗。 请教医生。 眼睛接触 用水冲洗眼睛作为预防措施。 食入 切勿给失去知觉者从嘴里喂食任何东西。 用水漱口。 请教医生。 4.2 主要症状和影响，急性和迟发效应 电解质失衡, 据我们所知，此化学，物理和毒性性质尚未经完整的研究。, 孕期接触到睾丸激素和它的酯会导致胎儿男性化。 4.3 及时的医疗处理和所需的特殊处理的说明和指示 无数据资料 模块5. 消防措施 5.1 灭火介质 灭火方法及灭火剂 用水雾,耐醇泡沫,干粉或二氧化碳灭火。 5.2 源于此物质或混合物的特别的危害 碳氧化物 5.3 给消防员的建议 如必要的话,戴自给式呼吸器去救火。 5.4 进一步信息 无数据资料 模块6. 泄露应急处理 6.1 人员的预防,防护设备和紧急处理程序 使用个人防护设备。 防止粉尘的生成。 防止吸入蒸汽、气雾或气体。 保证充分的通风。 将人员撤离到安全区域。 避免吸入粉尘。 6.2 环境保护措施 在确保安全的前提下，采取措施防止进一步的泄漏或溢出。 不要让产物进入下水道。 6.3 抑制和清除溢出物的方法和材料 收集、处理泄漏物，不要产生灰尘。 扫掉和铲掉。 存放进适当的闭口容器中待处理。 6.4 参考其他部分 丢弃处理请参阅第13节。 模块7. 操作处置与储存 7.1 安全操作的注意事项 避免接触皮肤和眼睛。 防止粉尘和气溶胶生成。避免曝露：使用前需要获得专门的指导。 在有粉尘生成的地方,提供合适的排风设备。一般性的防火保护措施。 7.2 安全储存的条件,包括任何不兼容性 贮存在阴凉处。 容器保持紧闭，储存在干燥通风处。 7.3 特定用途 无数据资料 模块8. 接触控制和个体防护 8.1 容许浓度 最高容许浓度 没有已知的国家规定的暴露极限。 8.2 暴露控制 适当的技术控制 按照良好工业和安全规范操作。 休息前和工作结束时洗手。 个体防护设备 眼/面保护 带有防护边罩的安全眼镜符合 EN166要求请使用经官方标准如NIOSH (美国) 或 EN 166(欧盟) 检测与批准的设备防护眼部。 皮肤保护 戴手套取 手套在使用前必须受检查。 请使用合适的方法脱除手套(不要接触手套外部表面),避免任何皮肤部位接触此产品. 使用后请将被污染过的手套根据相关法律法规和有效的实验室规章程序谨慎处理. 请清洗并吹干双手 所选择的保护手套必须符合EU的89/686/EEC规定和从它衍生出来的EN 376标准。 身体保护 全套防化学试剂工作服, 防护设备的类型必须根据特定工作场所中的危险物的浓度和含量来选择。 呼吸系统防护 如危险性评测显示需要使用空气净化的防毒面具，请使用全面罩式多功能微粒防毒面具N100型（US ）或P3型（EN 143）防毒面具筒作为工程控制的候补。如果防毒面具是保护的唯一方式，则使用全面罩式送风防毒 面具。 呼吸器使用经过测试并通过政府标准如NIOSH（US）或CEN（EU）的呼吸器和零件。 模块9. 理化特性 9.1 基本的理化特性的信息 a) 外观与性状 形状: 固体 b) 气味 无数据资料 c) 气味阈值 无数据资料 d) pH值 无数据资料 e) 熔点/凝固点 熔点/凝固点: 122 - 123 °C f) 起始沸点和沸程 无数据资料 g) 闪点 无数据资料 h) 蒸发速率 无数据资料 i) 易燃性(固体,气体) 无数据资料 j) 高的/低的燃烧性或爆炸性限度 无数据资料 k) 蒸汽压 无数据资料 l) 蒸汽密度 无数据资料 m) 相对密度 无数据资料 n) 水溶性 无数据资料 o) n-辛醇/水分配系数 无数据资料 p) 自燃温度 无数据资料 q) 分解温度 无数据资料 r) 粘度 无数据资料 模块10. 稳定性和反应活性 10.1 反应性 无数据资料 10.2 稳定性 无数据资料 10.3 危险反应的可能性 无数据资料 10.4 应避免的条件 无数据资料 10.5 不兼容的材料 强氧化剂, 强碱 10.6 危险的分解产物 其它分解产物 - 无数据资料 模块11. 毒理学资料 11.1 毒理学影响的信息 急性毒性 半数致死剂量 (LD50) 经口 - 大鼠 - 1,000 mg/kg 皮肤刺激或腐蚀 无数据资料 眼睛刺激或腐蚀 无数据资料 呼吸道或皮肤过敏 无数据资料 生殖细胞突变性 无数据资料 致癌性 该产品是或包含被IARC, ACGIH, EPA, 和 NTP 列为可能是致癌物的组分 可能的人类致癌物 IARC: 此产品中没有大于或等于 0。1%含量的组分被 IARC鉴别为可能的或肯定的人类致癌物。 生殖毒性 婴儿可能出现先天性畸形和畸形的危险 疑似人类生殖毒性 从实验动物的结果看，过度接触能导致生殖紊乱 特异性靶器官系统毒性（一次接触） 无数据资料 特异性靶器官系统毒性（反复接触） 无数据资料 吸入危险 无数据资料 潜在的健康影响 吸入吸入可能有害。 可能引起呼吸道刺激。 摄入误吞对人体有害。 皮肤如果通过皮肤吸收可能是有害的。 可能引起皮肤刺激。 眼睛可能引起眼睛刺激。 接触后的征兆和症状 电解质失衡, 据我们所知，此化学，物理和毒性性质尚未经完整的研究。, 孕期接触到睾丸激素和它的酯会导致胎儿男性化。 附加说明 化学物质毒性作用登记: XA3115000 模块12. 生态学资料 12.1 生态毒性 无数据资料 12.2 持久存留性和降解性 无数据资料 12.3 潜在的生物蓄积性 无数据资料 12.4 土壤中的迁移性 无数据资料 12.5 PBT 和 vPvB的结果评价 无数据资料 12.6 其它不利的影响 无数据资料 模块13. 废弃处置 13.1 废物处理方法 产品 将剩余的和未回收的溶液交给处理公司。 联系专业的拥有废弃物处理执照的机构来处理此物质。 与易燃溶剂相溶或者相混合，在备有燃烧后处理和洗刷作用的化学焚化炉中燃烧 受污染的容器和包装 作为未用过的产品弃置。 模块14. 运输信息 14.1 联合国危险货物编号 欧洲陆运危规: -国际海运危规: -国际空运危规: - 14.2 联合国（UN）规定的名称 欧洲陆运危规: 非危险货物 国际海运危规: 非危险货物 国际空运危规: 非危险货物 14.3 运输危险类别 欧洲陆运危规: -国际海运危规: -国际空运危规: - 14.4 包裹组 欧洲陆运危规: -国际海运危规: -国际空运危规: - 14.5 环境危险 欧洲陆运危规: 否国际海运危规 海运污染物: 否国际空运危规: 否 14.6 对使用者的特别提醒 无数据资料 参见发票或包装条的反面。 模块 15 - 法规信息 N/A 模块16 - 其他信息 N/A

毒性和生态

毒理学数据: 有致癌可能性 CHEMICAL IDENTIFICATION RTECS NUMBER : XA3115000 CHEMICAL NAME : Testosterone, propionate CAS REGISTRY NUMBER : 57-85-2 LAST UPDATED : 199706 DATA ITEMS CITED : 81 MOLECULAR FORMULA : C22-H32-O3 MOLECULAR WEIGHT : 344.54 WISWESSER LINE NOTATION : L E5 B666 OV MUTJ A1 E1 FOV2 -B&AEF HEALTH HAZARD DATA ACUTE TOXICITY DATA TYPE OF TEST : LD50 - Lethal dose, 50 percent kill ROUTE OF EXPOSURE : Oral SPECIES OBSERVED : Rodent - rat DOSE/DURATION : 1 gm/kg TOXIC EFFECTS : Details of toxic effects not reported other than lethal dose value TYPE OF TEST : LD50 - Lethal dose, 50 percent kill ROUTE OF EXPOSURE : Intraperitoneal SPECIES OBSERVED : Rodent - rat DOSE/DURATION : 585 mg/kg TOXIC EFFECTS : Details of toxic effects not reported other than lethal dose value TYPE OF TEST : LD50 - Lethal dose, 50 percent kill ROUTE OF EXPOSURE : Subcutaneous SPECIES OBSERVED : Rodent - rat DOSE/DURATION : >5 gm/kg TOXIC EFFECTS : Details of toxic effects not reported other than lethal dose value TYPE OF TEST : LD50 - Lethal dose, 50 percent kill ROUTE OF EXPOSURE : Oral SPECIES OBSERVED : Rodent - mouse DOSE/DURATION : 1350 mg/kg TOXIC EFFECTS : Details of toxic effects not reported other than lethal dose value TYPE OF TEST : LD50 - Lethal dose, 50 percent kill ROUTE OF EXPOSURE : Intraperitoneal SPECIES OBSERVED : Rodent - mouse DOSE/DURATION : 970 mg/kg TOXIC EFFECTS : Details of toxic effects not reported other than lethal dose value TYPE OF TEST : LD50 - Lethal dose, 50 percent kill ROUTE OF EXPOSURE : Subcutaneous SPECIES OBSERVED : Rodent - mouse DOSE/DURATION : >5 gm/kg TOXIC EFFECTS : Details of toxic effects not reported other than lethal dose value TYPE OF TEST : TDLo - Lowest published toxic dose ROUTE OF EXPOSURE : Intraperitoneal SPECIES OBSERVED : Rodent - rat DOSE/DURATION : 3900 mg/kg/26W-I TOXIC EFFECTS : Liver - changes in liver weight Kidney, Ureter, Bladder - changes in bladder weight Endocrine - changes in spleen weight TYPE OF TEST : TDLo - Lowest published toxic dose ROUTE OF EXPOSURE : Subcutaneous SPECIES OBSERVED : Rodent - rat DOSE/DURATION : 1560 mg/kg/26W-I TOXIC EFFECTS : Cardiac - changes in heart weight Kidney, Ureter, Bladder - changes in bladder weight Endocrine - changes in thymus weight TYPE OF TEST : TDLo - Lowest published toxic dose ROUTE OF EXPOSURE : Subcutaneous SPECIES OBSERVED : Rodent - rat DOSE/DURATION : 10 mg/kg TOXIC EFFECTS : Tumorigenic - neoplastic by RTECS criteria Skin and Appendages - tumors TYPE OF TEST : TDLo - Lowest published toxic dose ROUTE OF EXPOSURE : Implant SPECIES OBSERVED : Rodent - rat DOSE/DURATION : 432 mg/kg/48W-C TOXIC EFFECTS : Tumorigenic - equivocal tumorigenic agent by RTECS criteria Reproductive - Tumorigenic effects - prostate tumors TYPE OF TEST : TDLo - Lowest published toxic dose ROUTE OF EXPOSURE : Implant SPECIES OBSERVED : Rodent - mouse DOSE/DURATION : 5200 mg/kg/65W-I TOXIC EFFECTS : Tumorigenic - equivocal tumorigenic agent by RTECS criteria Lungs, Thorax, or Respiration - tumors Reproductive - Tumorigenic effects - uterine tumors TYPE OF TEST : TDLo - Lowest published toxic dose ROUTE OF EXPOSURE : Implant SPECIES OBSERVED : Rodent - hamster DOSE/DURATION : 360 mg/kg TOXIC EFFECTS : Tumorigenic - equivocal tumorigenic agent by RTECS criteria Musculoskeletal - tumors Reproductive - Tumorigenic effects - other reproductive system tumors TYPE OF TEST : TDLo - Lowest published toxic dose ROUTE OF EXPOSURE : Intramuscular DOSE : 10714 ug/kg SEX/DURATION : male 30 day(s) pre-mating TOXIC EFFECTS : Reproductive - Paternal Effects - spermatogenesis (incl. genetic material, sperm morphology, motility, and count) TYPE OF TEST : TDLo - Lowest published toxic dose ROUTE OF EXPOSURE : Intramuscular DOSE : 4286 ug/kg SEX/DURATION : male 14 day(s) pre-mating TOXIC EFFECTS : Reproductive - Paternal Effects - spermatogenesis (incl. genetic material, sperm morphology, motility, and count) TYPE OF TEST : TDLo - Lowest published toxic dose ROUTE OF EXPOSURE : Intramuscular DOSE : 3 mg/kg SEX/DURATION : female 6 day(s) pre-mating TOXIC EFFECTS : Reproductive - Maternal Effects - menstrual cycle changes or disorders TYPE OF TEST : TDLo - Lowest published toxic dose ROUTE OF EXPOSURE : Parenteral DOSE : 8570 ug/kg SEX/DURATION : male 24 day(s) pre-mating TOXIC EFFECTS : Reproductive - Paternal Effects - spermatogenesis (incl. genetic material, sperm morphology, motility, and count) Reproductive - Paternal Effects - testes, epididymis, sperm duct TYPE OF TEST : TDLo - Lowest published toxic dose ROUTE OF EXPOSURE : Parenteral DOSE : 18500 ug/kg SEX/DURATION : female 31 day(s) pre-mating TOXIC EFFECTS : Reproductive - Maternal Effects - menstrual cycle changes or disorders Reproductive - Fertility - other measures of fertility TYPE OF TEST : TDLo - Lowest published toxic dose ROUTE OF EXPOSURE : Oral DOSE : 100 mg/kg SEX/DURATION : female 17-20 day(s) after conception TOXIC EFFECTS : Reproductive - Specific Developmental Abnormalities - urogenital system TYPE OF TEST : TDLo - Lowest published toxic dose ROUTE OF EXPOSURE : Oral DOSE : 25 mg/kg SEX/DURATION : female 16-20 day(s) after conception TOXIC EFFECTS : Reproductive - Specific Developmental Abnormalities - urogenital system TYPE OF TEST : TDLo - Lowest published toxic dose ROUTE OF EXPOSURE : Intraperitoneal DOSE : 4550 mg/kg SEX/DURATION : male 26 week(s) pre-mating TOXIC EFFECTS : Reproductive - Paternal Effects - testes, epididymis, sperm duct Reproductive - Paternal Effects - prostate, seminal vesicle, Cowper's gland, accessory glands TYPE OF TEST : TDLo - Lowest published toxic dose ROUTE OF EXPOSURE : Intraperitoneal DOSE : 4550 mg/kg SEX/DURATION : female 26 week(s) pre-mating TOXIC EFFECTS : Reproductive - Maternal Effects - ovaries, fallopian tubes Reproductive - Maternal Effects - uterus, cervix, vagina TYPE OF TEST : TDLo - Lowest published toxic dose ROUTE OF EXPOSURE : Subcutaneous DOSE : 50 ug/kg SEX/DURATION : female 1 day(s) pre-mating TOXIC EFFECTS : Reproductive - Maternal Effects - ovaries, fallopian tubes Reproductive - Maternal Effects - uterus, cervix, vagina TYPE OF TEST : TDLo - Lowest published toxic dose ROUTE OF EXPOSURE : Subcutaneous DOSE : 200 ug/kg SEX/DURATION : male 20 day(s) pre-mating TOXIC EFFECTS : Reproductive - Paternal Effects - testes, epididymis, sperm duct TYPE OF TEST : TDLo - Lowest published toxic dose ROUTE OF EXPOSURE : Subcutaneous DOSE : 7500 ug/kg SEX/DURATION : female 17 day(s) after conception TOXIC EFFECTS : Reproductive - Specific Developmental Abnormalities - urogenital system Reproductive - Effects on Newborn - delayed effects TYPE OF TEST : TDLo - Lowest published toxic dose ROUTE OF EXPOSURE : Subcutaneous DOSE : 50 ug/kg SEX/DURATION : female 1 day(s) pre-mating TOXIC EFFECTS : Reproductive - Fertility - other measures of fertility TYPE OF TEST : TDLo - Lowest published toxic dose ROUTE OF EXPOSURE : Subcutaneous DOSE : 6250 ug/kg SEX/DURATION : female 15 day(s) after conception TOXIC EFFECTS : Reproductive - Specific Developmental Abnormalities - skin and skin appendages TYPE OF TEST : TDLo - Lowest published toxic dose ROUTE OF EXPOSURE : Subcutaneous DOSE : 6250 ug/kg SEX/DURATION : multigenerations TOXIC EFFECTS : Reproductive - Specific Developmental Abnormalities - urogenital system Reproductive - Effects on Newborn - growth statistics (e.g.%, reduced weight gain) TYPE OF TEST : TDLo - Lowest published toxic dose ROUTE OF EXPOSURE : Subcutaneous DOSE : 50 ug/kg SEX/DURATION : female 1 day(s) pre-mating TOXIC EFFECTS : Reproductive - Maternal Effects - menstrual cycle changes or disorders Reproductive - Fertility - mating performance (e.g. # sperm positive females per # females mated; # copulations per # estrus cycles) Reproductive - Fertility - female fertility index (e.g. # females pregnant per # sperm positive females; # females pregnant per # females mated) TYPE OF TEST : TDLo - Lowest published toxic dose ROUTE OF EXPOSURE : Intramuscular DOSE : 6250 ug/kg SEX/DURATION : female 1 day(s) pre-mating TOXIC EFFECTS : Reproductive - Maternal Effects - ovaries, fallopian tubes TYPE OF TEST : TDLo - Lowest published toxic dose ROUTE OF EXPOSURE : Intramuscular DOSE : 1200 ug/kg SEX/DURATION : female 9-14 day(s) after conception TOXIC EFFECTS : Reproductive - Fertility - litter size (e.g. # fetuses per litter; measured before birth) Reproductive - Specific Developmental Abnormalities - musculoskeletal system Reproductive - Effects on Newborn - growth statistics (e.g.%, reduced weight gain) TYPE OF TEST : TDLo - Lowest published toxic dose ROUTE OF EXPOSURE : Intramuscular DOSE : 3600 ug/kg SEX/DURATION : female 9-14 day(s) after conception TOXIC EFFECTS : Reproductive - Specific Developmental Abnormalities - urogenital system Reproductive - Effects on Newborn - live birth index (measured after birth) Reproductive - Effects on Newborn - weaning or lactation index (e.g., # alive at weaning per # alive at day 4) TYPE OF TEST : TDLo - Lowest published toxic dose ROUTE OF EXPOSURE : Intramuscular DOSE : 3600 ug/kg SEX/DURATION : female 9-14 day(s) after conception TOXIC EFFECTS : Reproductive - Effects on Embryo or Fetus - fetotoxicity (except death, e.g., stunted fetus) TYPE OF TEST : TDLo - Lowest published toxic dose ROUTE OF EXPOSURE : Intramuscular DOSE : 50 ug/kg SEX/DURATION : female 1 day(s) pre-mating TOXIC EFFECTS : Reproductive - Fertility - female fertility index (e.g. # females pregnant per # sperm positive females; # females pregnant per # females mated) TYPE OF TEST : TDLo - Lowest published toxic dose ROUTE OF EXPOSURE : Intracerebral DOSE : 10 ug/kg SEX/DURATION : female 77 day(s) pre-mating TOXIC EFFECTS : Reproductive - Maternal Effects - ovaries, fallopian tubes Reproductive - Maternal Effects - menstrual cycle changes or disorders Reproductive - Maternal Effects - other effects TYPE OF TEST : TDLo - Lowest published toxic dose ROUTE OF EXPOSURE : Parenteral DOSE : 15 mg/kg SEX/DURATION : female 15-20 day(s) after conception TOXIC EFFECTS : Reproductive - Effects on Newborn - behavioral TYPE OF TEST : TDLo - Lowest published toxic dose ROUTE OF EXPOSURE : Parenteral DOSE : 250 ug/kg SEX/DURATION : female 1 day(s) pre-mating TOXIC EFFECTS : Reproductive - Maternal Effects - ovaries, fallopian tubes Reproductive - Fertility - other measures of fertility TYPE OF TEST : TDLo - Lowest published toxic dose ROUTE OF EXPOSURE : Parenteral DOSE : 500 ug/kg SEX/DURATION : female 1 day(s) pre-mating TOXIC EFFECTS : Reproductive - Maternal Effects - uterus, cervix, vagina TYPE OF TEST : TDLo - Lowest published toxic dose ROUTE OF EXPOSURE : Parenteral DOSE : 92 mg/kg SEX/DURATION : male 23 day(s) pre-mating TOXIC EFFECTS : Reproductive - Fertility - mating performance (e.g. # sperm positive females per # females mated; # copulations per # estrus cycles) TYPE OF TEST : TDLo - Lowest published toxic dose ROUTE OF EXPOSURE : Implant DOSE : 10 ug/kg SEX/DURATION : female 77 day(s) pre-mating TOXIC EFFECTS : Reproductive - Maternal Effects - ovaries, fallopian tubes Reproductive - Maternal Effects - uterus, cervix, vagina Reproductive - Maternal Effects - menstrual cycle changes or disorders TYPE OF TEST : TDLo - Lowest published toxic dose ROUTE OF EXPOSURE : Implant DOSE : 30 ug/kg SEX/DURATION : female 77 day(s) pre-mating TOXIC EFFECTS : Reproductive - Maternal Effects - other effects TYPE OF TEST : TDLo - Lowest published toxic dose ROUTE OF EXPOSURE : Unreported DOSE : 20 mg/kg SEX/DURATION : male 5 day(s) pre-mating TOXIC EFFECTS : Reproductive - Fertility - mating performance (e.g. # sperm positive females per # females mated; # copulations per # estrus cycles) TYPE OF TEST : TDLo - Lowest published toxic dose ROUTE OF EXPOSURE : Unreported DOSE : 3500 mg/kg SEX/DURATION : female 10-16 day(s) after conception TOXIC EFFECTS : Reproductive - Fertility - female fertility index (e.g. # females pregnant per # sperm positive females; # females pregnant per # females mated) Reproductive - Fertility - post-implantation mortality (e.g. dead and/or resorbed implants per total number of implants) Reproductive - Effects on Embryo or Fetus - fetal death TYPE OF TEST : TDLo - Lowest published toxic dose ROUTE OF EXPOSURE : Multiple routes DOSE : 52500 ug/kg SEX/DURATION : female 15 day(s) pre-mating TOXIC EFFECTS : Reproductive - Maternal Effects - other effects TYPE OF TEST : TDLo - Lowest published toxic dose ROUTE OF EXPOSURE : Subcutaneous DOSE : 4 mg/kg SEX/DURATION : male 1 day(s) pre-mating TOXIC EFFECTS : Reproductive - Paternal Effects - testes, epididymis, sperm duct Reproductive - Fertility - mating performance (e.g. # sperm positive females per # females mated; # copulations per # estrus cycles) TYPE OF TEST : TDLo - Lowest published toxic dose ROUTE OF EXPOSURE : Subcutaneous DOSE : 200 mg/kg SEX/DURATION : female 12 day(s) after conception TOXIC EFFECTS : Reproductive - Specific Developmental Abnormalities - skin and skin appendages TYPE OF TEST : TDLo - Lowest published toxic dose ROUTE OF EXPOSURE : Subcutaneous DOSE : 40 mg/kg SEX/DURATION : female 1 day(s) pre-mating TOXIC EFFECTS : Reproductive - Fertility - female fertility index (e.g. # females pregnant per # sperm positive females; # females pregnant per # females mated) TYPE OF TEST : TDLo - Lowest published toxic dose ROUTE OF EXPOSURE : Subcutaneous DOSE : 20 mg/kg SEX/DURATION : female 10 day(s) pre-mating TOXIC EFFECTS : Reproductive - Maternal Effects - other effects TYPE OF TEST : TDLo - Lowest published toxic dose ROUTE OF EXPOSURE : Subcutaneous DOSE : 190 mg/kg SEX/DURATION : male 35 day(s) pre-mating TOXIC EFFECTS : Reproductive - Paternal Effects - prostate, seminal vesicle, Cowper's gland, accessory glands TYPE OF TEST : TDLo - Lowest published toxic dose ROUTE OF EXPOSURE : Intramuscular DOSE : 15 mg/kg SEX/DURATION : female 7-12 day(s) after conception TOXIC EFFECTS : Reproductive - Specific Developmental Abnormalities - musculoskeletal system Reproductive - Specific Developmental Abnormalities - urogenital system Reproductive - Effects on Newborn - growth statistics (e.g.%, reduced weight gain) TYPE OF TEST : TDLo - Lowest published toxic dose ROUTE OF EXPOSURE : Intramuscular DOSE : 15 mg/kg SEX/DURATION : female 7-12 day(s) after conception TOXIC EFFECTS : Reproductive - Fertility - litter size (e.g. # fetuses per litter; measured before birth) Reproductive - Effects on Embryo or Fetus - fetotoxicity (except death, e.g., stunted fetus) TYPE OF TEST : TDLo - Lowest published toxic dose ROUTE OF EXPOSURE : Intramuscular DOSE : 240 mg/kg SEX/DURATION : female 7-12 day(s) after conception TOXIC EFFECTS : Reproductive - Specific Developmental Abnormalities - eye/ear TYPE OF TEST : TDLo - Lowest published toxic dose ROUTE OF EXPOSURE : Intracerebral DOSE : 2 mg/kg SEX/DURATION : female 1 day(s) pre-mating TOXIC EFFECTS : Reproductive - Maternal Effects - ovaries, fallopian tubes TYPE OF TEST : TDLo - Lowest published toxic dose ROUTE OF EXPOSURE : Intracerebral DOSE : 2 mg/kg SEX/DURATION : male 1 day(s) pre-mating TOXIC EFFECTS : Reproductive - Paternal Effects - spermatogenesis (incl. genetic material, sperm morphology, motility, and count) TYPE OF TEST : TDLo - Lowest published toxic dose ROUTE OF EXPOSURE : Intramuscular DOSE : 30 mg/kg SEX/DURATION : male 60 day(s) pre-mating TOXIC EFFECTS : Reproductive - Paternal Effects - spermatogenesis (incl. genetic material, sperm morphology, motility, and count) Reproductive - Paternal Effects - testes, epididymis, sperm duct TYPE OF TEST : TDLo - Lowest published toxic dose ROUTE OF EXPOSURE : Oral DOSE : 24500 ug/kg SEX/DURATION : male 49 day(s) pre-mating TOXIC EFFECTS : Reproductive - Paternal Effects - spermatogenesis (incl. genetic material, sperm morphology, motility, and count) Reproductive - Fertility - male fertility index (e.g. # males impregnating females per # males exposed to fertile nonpregnant females) TYPE OF TEST : TDLo - Lowest published toxic dose ROUTE OF EXPOSURE : Subcutaneous DOSE : 1500 ug/kg SEX/DURATION : female 27-29 day(s) after conception TOXIC EFFECTS : Reproductive - Maternal Effects - postpartum Reproductive - Fertility - post-implantation mortality (e.g. dead and/or resorbed implants per total number of implants) Reproductive - Fertility - abortion TYPE OF TEST : TDLo - Lowest published toxic dose ROUTE OF EXPOSURE : Subcutaneous DOSE : 10 mg/kg SEX/DURATION : female 5 day(s) pre-mating TOXIC EFFECTS : Reproductive - Maternal Effects - uterus, cervix, vagina TYPE OF TEST : TDLo - Lowest published toxic dose ROUTE OF EXPOSURE : Subcutaneous DOSE : 500 ug/kg SEX/DURATION : male 1 day(s) pre-mating TOXIC EFFECTS : Reproductive - Fertility - mating performance (e.g. # sperm positive females per # females mated; # copulations per # estrus cycles) TYPE OF TEST : TDLo - Lowest published toxic dose ROUTE OF EXPOSURE : Intramuscular DOSE : 15750 ug/kg SEX/DURATION : male 21 day(s) pre-mating TOXIC EFFECTS : Reproductive - Paternal Effects - spermatogenesis (incl. genetic material, sperm morphology, motility, and count) TYPE OF TEST : TDLo - Lowest published toxic dose ROUTE OF EXPOSURE : Intramuscular DOSE : 142 mg/kg SEX/DURATION : female 40-77 day(s) after conception TOXIC EFFECTS : Reproductive - Specific Developmental Abnormalities - urogenital system Reproductive - Effects on Newborn - delayed effects TYPE OF TEST : TDLo - Lowest published toxic dose ROUTE OF EXPOSURE : Intramuscular DOSE : 140 mg/kg SEX/DURATION : female 29-35 day(s) after conception TOXIC EFFECTS : Reproductive - Maternal Effects - menstrual cycle changes or disorders TYPE OF TEST : TDLo - Lowest published toxic dose ROUTE OF EXPOSURE : Intramuscular DOSE : 140 mg/kg SEX/DURATION : female 39-45 day(s) after conception TOXIC EFFECTS : Reproductive - Maternal Effects - menstrual cycle changes or disorders TYPE OF TEST : TDLo - Lowest published toxic dose ROUTE OF EXPOSURE : Subcutaneous DOSE : 80 mg/kg SEX/DURATION : female 30-45 day(s) after conception TOXIC EFFECTS : Reproductive - Fertility - mating performance (e.g. # sperm positive females per # females mated; # copulations per # estrus cycles) Reproductive - Maternal Effects - menstrual cycle changes or disorders Reproductive - Specific Developmental Abnormalities - urogenital system TYPE OF TEST : TDLo - Lowest published toxic dose ROUTE OF EXPOSURE : Subcutaneous DOSE : 150 mg/kg SEX/DURATION : female 28-58 day(s) after conception TOXIC EFFECTS : Reproductive - Effects on Newborn - delayed effects TYPE OF TEST : TDLo - Lowest published toxic dose ROUTE OF EXPOSURE : Intramuscular DOSE : 110 mg/kg SEX/DURATION : female 50 day(s) pre-mating TOXIC EFFECTS : Reproductive - Maternal Effects - other effects Reproductive - Fertility - male fertility index (e.g. # males impregnating females per # males exposed to fertile nonpregnant females) TYPE OF TEST : TDLo - Lowest published toxic dose ROUTE OF EXPOSURE : Parenteral DOSE : 98 mg/kg SEX/DURATION : female 24-68 day(s) after conception TOXIC EFFECTS : Reproductive - Specific Developmental Abnormalities - urogenital system Reproductive - Effects on Newborn - delayed effects TYPE OF TEST : TDLo - Lowest published toxic dose ROUTE OF EXPOSURE : Subcutaneous DOSE : 1575 ug/kg SEX/DURATION : male 9 day(s) pre-mating TOXIC EFFECTS : Reproductive - Paternal Effects - prostate, seminal vesicle, Cowper's gland, accessory glands TYPE OF TEST : TDLo - Lowest published toxic dose ROUTE OF EXPOSURE : Subcutaneous DOSE : 5500 ug/kg SEX/DURATION : female 40-60 day(s) after conception TOXIC EFFECTS : Reproductive - Specific Developmental Abnormalities - urogenital system TYPE OF TEST : TDLo - Lowest published toxic dose ROUTE OF EXPOSURE : Subcutaneous DOSE : 693 mg/kg SEX/DURATION : female 40-60 day(s) after conception TOXIC EFFECTS : Reproductive - Specific Developmental Abnormalities - endocrine system Reproductive - Effects on Newborn - biochemical and metabolic TYPE OF TEST : TDLo - Lowest published toxic dose ROUTE OF EXPOSURE : Implant DOSE : 3045 ug/kg SEX/DURATION : female 40-60 day(s) after conception TOXIC EFFECTS : Reproductive - Effects on Newborn - growth statistics (e.g.%, reduced weight gain) Reproductive - Effects on Newborn - biochemical and metabolic Reproductive - Effects on Newborn - physical TYPE OF TEST : Cytogenetic analysis TYPE OF TEST : Sperm Morphology TYPE OF TEST : Sperm Morphology MUTATION DATA TYPE OF TEST : Morphological transformation TEST SYSTEM : Rodent - hamster Embryo DOSE/DURATION : 1 mg/L REFERENCE : CRNGDP Carcinogenesis (London). (Oxford Univ. Press, Pinkhill House, Southfield Road, Eynsham, Oxford OX8 1JJ, UK) V.1- 1980- Volume(issue)/page/year: 16,1329,1995 *** REVIEWS *** IARC Cancer Review:Animal Sufficient Evidence IMEMDT IARC Monographs on the Evaluation of Carcinogenic Risk of Chemicals to Man. (WHO Publications Centre USA, 49 Sheridan Ave., Albany, NY 12210) V.1- 1972- Volume(issue)/page/year: 21,519,1979 TOXICOLOGY REVIEW CANCAR Cancer (Philadelphia). (Lippincott/Harper, Journal Fulfillment Dept., 2350 Virginia Ave., Hagerstown, MD 21740) V.1- 1948- Volume(issue)/page/year: 40,1825,1977 TOXICOLOGY REVIEW ACRSAJ Advances in Cancer Research. (Academic Press, Inc., 465 S. Lincoln Dr., Troy, MO 63379) V.1- 1953- Volume(issue)/page/year: 1,173,1953 *** NIOSH STANDARDS DEVELOPMENT AND SURVEILLANCE DATA *** NIOSH OCCUPATIONAL EXPOSURE SURVEY DATA : NOES - National Occupational Exposure Survey (1983) NOES Hazard Code - X6098 No. of Facilities: 7 (estimated) No. of Industries: 1 No. of Occupations: 2 No. of Employees: 628 (estimated) No. of Female Employees: 314 (estimated)

安全

• 符号: GHS07, GHS08
• 信号词: Danger
• 危害声明: H302-H350-H361
• 警示性声明: P201-P280-P301 + P312 + P330-P308 + P313
• 个人防护装备: Eyeshields;full-face particle respirator type N100 (US);Gloves;respirator cartridge type N100 (US);type P1 (EN143) respirator filter;type P3 (EN 143) respirator cartridges
• 危害码 (欧洲): T
• 风险声明 (欧洲): R45
• 安全声明 (欧洲): S53-S36/37-S45
• 危险品运输编码: 2811
• WGK德国: 3
• RTECS号: XA3115000
• 海关编码: 2937290090

合成路线

58-22-0 79-03-8 ~% 57-85-2

文献：Journal of the American Chemical Society, , vol. 71, p. 3372

38859-47-1 ~% 57-85-2

文献：CH229140 , ;

58-22-0 123-62-6 ~% 57-85-2

文献：FIAT Final Rep.Nr.996<1947>59 Helvetica Chimica Acta, , vol. 19, p. 1141,1142 Anm. 4

4076-66-8 ~% 57-85-2

文献：CH241646 , ; US2374370 , ; US2311067 , ;

63088-08-4 ~% 57-85-2

文献：DE712857 , ; DRP/DRBP Org.Chem.

521-17-5 ~% 57-85-2

文献：Zhurnal Obshchei Khimii, , vol. 15, p. 661,664 Chem.Abstr., , p. 5879

上下游产品

上游产品  7
58-22-0 79-03-8 38859-47-1 123-62-6
4076-66-8 63088-08-4 521-17-5
下游产品  3
58-22-0 1156-92-9 60397-35-5

制备

睾酮在吡啶的存在下用丙酰氯酰化而制得。

海关

海关编码	2937290090